Connect Biopharma is a clinical-stage biopharmaceutical company developing rademikibart, a monoclonal antibody targeting interleukin-4-receptor alpha to treat asthma and chronic obstructive pulmonary disease. The company addresses substantial unmet medical needs in respiratory disease, pursuing an acute-to-chronic development strategy where patients experiencing acute exacerbations may transition to chronic maintenance therapy. Connect generates revenue through licensing agreements, including a partnership with Simcere Pharmaceutical for Greater China rights, and plans to commercialize rademikibart through regulatory approvals and third-party payers in various markets; the company owns extensive intellectual property expected to provide patent protection through the late 2030s.